Literature DB >> 10413086

Mutational analysis of subunit i beta2 (MECL-1) demonstrates conservation of cleavage specificity between yeast and mammalian proteasomes.

U Salzmann1, S Kral, B Braun, S Standera, M Schmidt, P M Kloetzel, A Sijts.   

Abstract

Proteasomes are the major protein-degrading complexes in the cytosol and regulate many cellular processes. To examine the functional importance of the MC14/MECL-1 proteasome active site subunits, cell lines expressing a catalytically inactive form of MECL-1 were established. Whereas mutant MECL-1 was readily incorporated into cytosolic proteasomes, replacing the constitutive MC14 subunit, removal of the prosequence was incomplete indicating that its processing required autocatalytic cleavage. Functional analyses showed that the absence of the MC14/MECL-1 active sites abrogated proteasomal trypsin-like activity, but did not affect other catalytic activities. Our data demonstrate a conservation of cleavage specificity between mammalian and yeast proteasomes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10413086     DOI: 10.1016/s0014-5793(99)00768-1

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  9 in total

1.  The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses.

Authors:  K Schwarz; R de Giuli; G Schmidtke; S Kostka; M van den Broek; K B Kim; C M Crews; R Kraft; M Groettrup
Journal:  J Immunol       Date:  2000-06-15       Impact factor: 5.422

Review 2.  The ubiquitin-proteasome pathway and proteasome inhibitors.

Authors:  J Myung; K B Kim; C M Crews
Journal:  Med Res Rev       Date:  2001-07       Impact factor: 12.944

3.  Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.

Authors:  Deborah J Kuhn; Sally A Hunsucker; Qing Chen; Peter M Voorhees; Marian Orlowski; Robert Z Orlowski
Journal:  Blood       Date:  2008-12-02       Impact factor: 22.113

4.  LMP2-specific inhibitors: chemical genetic tools for proteasome biology.

Authors:  Yik Khuan Ho; Paola Bargagna-Mohan; Marie Wehenkel; Royce Mohan; Kyung-Bo Kim
Journal:  Chem Biol       Date:  2007-04

Review 5.  Subunit specific inhibitors of proteasomes and their potential for immunomodulation.

Authors:  Alexei F Kisselev; Marcus Groettrup
Journal:  Curr Opin Chem Biol       Date:  2014-09-15       Impact factor: 8.822

6.  Differential intra-proteasome interactions involving standard and immunosubunits.

Authors:  Krupakar Jayarapu; Thomas A Griffin
Journal:  Biochem Biophys Res Commun       Date:  2007-05-11       Impact factor: 3.575

7.  Efficient generation of a hepatitis B virus cytotoxic T lymphocyte epitope requires the structural features of immunoproteasomes.

Authors:  A J Sijts; T Ruppert; B Rehermann; M Schmidt; U Koszinowski; P M Kloetzel
Journal:  J Exp Med       Date:  2000-02-07       Impact factor: 14.307

Review 8.  Human Tumor Antigens and Cancer Immunotherapy.

Authors:  Nathalie Vigneron
Journal:  Biomed Res Int       Date:  2015-06-16       Impact factor: 3.411

9.  Pro-inflammatory Cytokines Alter the Immunopeptidome Landscape by Modulation of HLA-B Expression.

Authors:  Aaron Javitt; Eilon Barnea; Matthias P Kramer; Hila Wolf-Levy; Yishai Levin; Arie Admon; Yifat Merbl
Journal:  Front Immunol       Date:  2019-02-18       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.